Gilbert Technologies is committed to improving patient care when using drugs that cause unpleasant conditions when using medication. Our first focus area is on patients with respiratory diseases.
The applications are developed in this order:
5. Other lung indications
a. COPD (Chronic Obstructive Pulmonary Disease)
b. IPF (Idiopathic Pulmonary Fibrosis)
c. non-CF Bronchiectasis
6. Systemic indication
a. BCP (Breakthrough Cancer Pain)
We believe our inhalers can be positioned as a superior inhaler offering better outcomes, higher patient convenience and hence better patient adherence. Our inhalers can be positioned as a competitive differentiator to either branded proprietary, generic or brand-less generic pharmaceuticals, enabling inhalation of new and/or more complex molecules (for instance biologicals). Therefore, we at Gilbert Technologies aim to become the new competitive differentiator and entry barrier in a market where generics are replacing branded medication.
For pulmonary vaccinations, acute migraine, diabetes and other indications new patented technology are under development.
The actual applications we focus on is much more extensive and will be dealt with on the basis of progressive insight.
• Lode B.V.
• NHL University of Applied Sciences
• University Medical Centre Utrecht
• TU Delft
Gilbert Technologies BV
P.O. Box 6
1400 AA Bussum – NL
Gilbert Technologies 2017